Tianjin University of Traditional Chinese Medicine   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tianjin China (1958)

Organization Overview

First Clinical Trial
2006
NCT00506337
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Second Affiliated Hospital of Tianjin University of TCM | Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine | The First Affiliated Hospital of Tianjing University of Traditional Chinese Medicine | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine，China | Tianjin Nankai Hospital | Tianjin University of Traditional Chinese Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute-On-Chronic Liver Failure (Phase 2)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Cerebral Infarction (Phase 4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Disease (Phase 3)

End Stage Liver Disease (Phase 2)

Gastroesophageal Reflux (Phase 1)

Hepatic Insufficiency (Phase 2)

Hypersensitivity (Phase 4)

Ischemia (Phase 4)

Kidney Diseases (Phase 4)

Liver Failure (Phase 2)

Liver Failure, Acute (Phase 2)

Pancreatitis (Phase 3)

Pancreatitis, Acute Necrotizing (Phase 3)

Pelvic Infection (Phase 4)

Pelvic Inflammatory Disease (Phase 4)

Prostatic Neoplasms (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Stroke (Phase 4)

Tic Disorders (Phase 3)

Tics (Phase 3)

Tourette Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 48